Further €1 million investment by Randox Teo. in Dungloe as the company purchases facility from Údarás na Gaeltachta

26 September, 2011

min read

Randox Teo today (26 Sept) demonstrated its commitment to secure and develop its Diagnostic and R&D facility in Dungloe by purchasing the building it currently leases from Údarás na Gaeltachta.

The Minister of State at the Department of Arts, Heritage and the Gaeltacht, Dinny Mc Ginley TD, who met the company’s CEO Peter Fitzgerald in Dungloe today where the official documents were being signed said that “The decision by Randox Laboratories Ltd to acquire this sizeable asset in Dungloe is a vote of confidence in the area and the company’s future in Dungloe.”

Three years ago Randox Laboratories Ltd announced that it was to establish a diagnostic manufacturing and R&D facility in Dungloe with a total investment of €7.5 million with assistance from Údarás na Gaeltachta. Randox Teo currently employs 20 people at this facility and the company expects this number to increase substantially in the next 12 months.

Peter Fitzgerald, CEO of Randox Teo said “We are delighted with our facility here in Dungloe. We expect, as we ramp up our manufacturing and R&D departments, that we will substantially increase our levels of employees.”

Randox Laboratories manufactures a range of products that are used in over 145 countries worldwide by hospitals, research and forensic laboratories, pharmaceutical companies, sports testing authorities and veterinary clinics. The Randox facility in Dungloe currently supplies the company’s clinical analyser product and houses one of the company’s main R&D laboratories. Randox Teo will begin to manufacture biochips in the in the next few months and is awaiting the arrival of specially constructed manufacturing line for this purpose. These revolutionary biochips will be used in hospitals worldwide to aid in the diagnosis of disease conditions. Randox were the first company in the world to produce an automated protein biochip, used for multi-analyte testing. The biochips allow clinicians and researchers to screen for multiple conditions in a single patient blood sample.